Healthcare / Medical Instruments & SuppliesTokyo
$2264.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $536.8M · quality 81.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
52/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$10.0B
P/E
21.3x
↑EV/EBITDA
7.2x
↓ROE
9.5%
↑Gross Margin
50.4%
↑Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.8%
FCF CAGR
+10.7%
FCF margin
11.8%
FCF / Net income
0.98x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.31B · net income $641.0M · FCF $627.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.31B | $5.31B | $5.06B | $4.92B | $4.61B |
| Net Income | $641.0M | $641.0M | $638.0M | $568.2M | $512.3M |
| EBITDA | $936.9M | $936.9M | $1.06B | $994.3M | $924.9M |
| EPS | 152.06 | 152.06 | 152.26 | 136.13 | 126.39 |
| Gross Margin | 50.4% | 50.4% | 50.5% | 51.1% | 52.2% |
| Operating Margin | 15.5% | 15.5% | 17.1% | 16.7% | 16.2% |
| Net Margin | 12.1% | 12.1% | 12.6% | 11.5% | 11.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.09 | 0.09 | 0.14 | 0.17 | 0.18 |
| Current Ratio | 1.02 | 1.02 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $627.8M | $627.8M | $354.9M | $536.8M | $463.2M |
| Returns | |||||
| ROE | 9.5% | 9.5% | 10.2% | 10.0% | 9.9% |
| Valuation | |||||
| P/E | 21.32 | 21.32 | 8.01 | 7.57 | 8.30 |
| EV/EBITDA | 7.23 | 7.23 | 2.65 | 2.23 | 2.73 |
| P/B | 1.41 | 1.41 | 0.82 | 0.76 | 0.82 |
| Growth & Yield | |||||
| Revenue Growth | 4.9% | 4.9% | 2.7% | 6.7% | — |
| EPS Growth | -0.1% | -0.1% | 11.8% | 7.7% | — |
| Dividend Yield | 2.8% | 2.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
9.7%
EPS terminal req.
$200.89
Spread vs growth
-9.9%
5Y implied EPS CAGR
9.8%
EPS terminal req.
$243.08
Spread vs growth
-10.0%
10Y implied EPS CAGR
9.9%
EPS terminal req.
$391.48
Spread vs growth
-10.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+84.2%
Start / end P/E
8.2x → 14.9x
EPS bridge
152.26 → 152.06
Residual
-0.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.